Association of hypertension and dyslipidaemia with increasing obesity in patients with Type 2 Diabetes Mellitus by Saleem, Zikria et al.
Braz. J. Pharm. Sci. 2019;55:e18136 Page 1 / 9
Brazilian Journal of 
Pharmaceutical Sciences
http://dx.doi.org/10.1590/s2175-97902019000118136
A
rt
ic
le
*Correspondence: H. Saeed. Department of Clinical Pharmacy, University 
College of Pharmacy, University of the Punjab, Allama Iqbal Campus, 54000, 
Lahore, Pakistan University College of Pharmacy, University of the Punjab. 
Tel.: 0092-304-880-1243. E-mail: hamid.pharmacy@pu.edu.pk 
Association of hypertension and dyslipidaemia with increasing 
obesity in patients with Type 2 Diabetes Mellitus
Zikria Saleem1, Hamid Saeed*1, Zohaib Abbas Khan2, Muhammad Imran Hassan Khan3, Furqan 
Khurshid Hashmi1, Muhammad Islam1, Afzaal Bashir4, Saleha Sadeeqa5
1Department of Clinical Pharmacy, University College of Pharmacy, University of the Punjab, Allama Iqbal Campus, 54000, 
Lahore, Pakistan, 2Department of Pharmacology, University College of Pharmacy, University of the Punjab, Allama Iqbal 
Campus, 54000, Lahore, Pakistan, 3Diabetes, Endocrine and Metabolic Centre (DEMC), Lahore General Hospital, Lahore, 
Pakistan, 4King Edward Medical University (KEMU), Lahore, Pakistan, 5Institute of Pharmacy, Lahore College for Women 
University, Jail Road, Lahore, Pakistan
The study was performed to estimate the association of hypertension and dyslipidaemia with increasing 
body weight and obesity in Type II diabetics of Lahore, Pakistan. An observational study was conducted 
by enrolling 2708 obese diabetics from four diabetes care centres of Lahore, Pakistan. Data was collected 
for a period of 7 months. Associations were estimated using chi-square, binary and multinomial logistic 
regression. Data suggested that blood pressure, systolic and diastolic, exhibited continual increase with 
increasing body weight and obesity class in diabetes patients with 41.8% increase in the prevalence of 
hypertension in obesity class III subjects (OR; 1.91, p=0.02). Likewise, triglycerides and total cholesterol 
exhibited continual increase in their mean values with increasing obesity, i-e., an overall increase in the 
prevalence of dyslipidaemia of 27.2% in obesity class 3 subjects (OR; 1.94, p=0.29). Taken together, 
this data suggested that hypertension is potentially associated with increasing obesity in diabetics, while 
dyslipidaemia demonstrated plausible association only with obesity class 3.
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INTRODUCTION
Despite recent advancements in diabetes research, 
the worldwide prevalence of diabetes continues to grow, 
i-e., 2.8% in 2000 and is estimated to be ~ 4.4% in 2030 
with projected increase from 171 million in 2000 to 
above 350 million in 2030 (Wild et al., 2004). Besides, 
diabetes has been associated with higher incidence 
of hospitalization, blindness, renal failure and non-
traumatic amputation, majorly contributing towards 
escalating healthcare costs (Rubin, Altman, Mendelson, 
1994). According to World Health Organization (WHO) 
estimates, the global number of diabetics will likely to 
double over the next 25 years and during this period, the 
larger burden of the disease will be shared by developing 
nations – particularly South Asian countries (Amos, 
McCarty, Zimmet, 1997). Pakistan belongs to a high 
prevalence area, ranked 7th globally, having 6.9 million 
people in 2010 and is expected to double in 2025 affecting 
11.9 million people (Qidwai, Ashfaq, 2010; Whiting et 
al., 2011). 
Numerous literature evidences suggest that 
hypertension and obesity increase the risk of long term 
vascular complications and these risks become more 
detrimental due to limited access to health care and 
inadequate prevention of concomitant diseases, such 
as chronic kidney disease, stroke, peripheral vascular 
disease and heart disease (Colosia, Palencia, Khan, 2013). 
Additionally, the relative risk of developing cardiovascular 
diseases in diabetics is more than double compared to non-
diabetics counterparts. Besides, in developing countries 
limited access and inadequate prevention strategies further 
aggravate the debilitating complications in diabetics 
(Kennel, McGee, 1979; Yusuf et al., 2001). Studies 
have also shown that optimal blood pressure control and 
within range lipid profiles confer cardiovascular benefits 
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in patients with type II diabetes (AdLer et al., 2000; 
LeRoith, 2008) – a reduction in 10 mmHg systolic blood 
pressure was associated with risk reduction of 12% in 
diabetic complications, 15% in diabetes related deaths, 
11% in myocardial infarction and 13% in microvascular 
complications (AdLer et al., 2000; LeRoith, 2008). 
Likewise, reduction in the levels of low-density lipoprotein 
cholesterol (LDL-C) resulted in lower incidence of major 
coronary artery risks in diabetics (Berry, Tardif, Bourassa, 
2007). Seemingly, obesity acts as an insidious player in 
the patho-physiology of hypertension and diabetes, hence 
clustering of risk factors seems to have a greater impact 
on worse disease outcomes rather than individual risk 
factors (Song, Hardisty, 2008). Notably, abdominal obesity 
in diabetics along with multifactorial pathophysiology 
of dyslipidemia leads to augmented risk of mortality for 
coronary artery disease (Carr, Brunzell, 2004; Franssen 
et al., 2011; Yoshino, Hirano, Kazumi, 1996). NHANES 
studies (1999 to 2004) showed that patients with obesity 
have double chances of developing dyslipidaemia than 
those with normal weight (Yoshino, Hirano, Kazumi, 
1996). Thus, metabolic syndrome, such as diabetes with 
concomitant presence of hypertension, dyslipidaemia, 
pro-inflammatory and prothrombic states can contribute 
towards complex pathological conditions involving 
multiple pathways (LeRoith, 2008). Yet, a very few 
literature evidences exist that evaluated the association 
of hypertension and dyslipidaemia in obese diabetics - 
not a single study from Pakistan. Thus, the present study, 
the first study, was aimed at examining the association of 
hypertension, dyslipidaemia with obesity in diabetics of 
Lahore, Pakistan.
METHODS
Ethical approval
Ethical approval for the study was obtained from the 
human ethics committee, University College of Pharmacy, 
University of the Punjab, reference #; EC/UCP/122/2015. 
All the procedures were in accordance with the principles 
of the declaration of Helsinki 1975 and its ensuing 
amendments (Association WM, 2009).
Study design
An observational study from December 2015 to 
June 2016, 7 months, was conducted by enrolling 2708 
patients from tertiary care public hospitals of Lahore, 
Pakistan. Diabetics were identified from the hospital health 
information system as per clinician’s confirmed diagnosis. 
All the necessary data, as per study objectives, were 
retrieved from patient’s medical profiles made accessible 
upon approval of the study from hospital administration. 
Data was obtained from Lahore General Hospital (LGH), 
Mayo Hospital Lahore, Diabetes Management Centre 
(DMC) and Services Hospital Lahore. Patient’s data was 
then segregated according to body mass index (BMI, kg/
m2) described below;
Obesity
Degree of obesity was categorized as per National 
Heart, Lung and Blood Institute’s definition for overweight 
and obesity (Initiative NOE et al., 2002). Body mass index 
(BMI, kg/m2) was calculated using the formula given 
below:
BMI based weight categories include, underweight; 
< 18.5 kg/m2, normal weight; 18.5 – 24.9 kg/m2and 
overweight; 25 - 29.9 kg/m2. Obesity was classified into 
three classes; Obesity class I; 30 - 34.9 kg/m2, Obesity 
class II; 35 - 39.9 kg/m2 and Obesity class III; >40 kg/m2.
STUDY POPULATION
Potential subjects were identified from hospitals 
databases and included in the study as per approved 
inclusion and exclusion criteria.
Inclusion Criteria: All uncontrolled diabetics, 
HbA1c above 7%, irrespective of gender, ethnicity and 
area of residence, above 25 years of age, sans any chronic 
kidney disease or mental health issues were included in the 
study. All the participants must have a disease (diabetes) 
duration of more than 5 years at the time of enrolment 
and were visiting the hospitals from December 2015 to 
June 2016.
Exclusion criteria: all controlled diabetic patients, 
below 25 years of age, having impaired cognition and 
had a disease duration of less than 5 years were excluded 
from the study. 
Study endpoints
Following endpoints were considered as per 
standard guidelines;
Diabetes Mellitus (DM)
Patients having diabetes (type II) were identified 
from hospital medical records as per physician’s 
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evaluation of successive blood glucose tests, i-e., patient’s 
having fasting glucose > 125 mg/dL, having HbA1c 
levels > 7%. DM was defined according to the levels of 
HbA1c as defined by American Diabetes Association 
(ADA) Guidelines 2015. HbA1c levels of < 7% and > 
7% were considered controlled and uncontrolled diabetes, 
respectively (Association AD, 2015). 
Hypertension
Participants were considered hypertensive if their 
systolic and diastolic blood pressure was > 140 and 90 
mmHg, respectively. Hypertensive patients were classified 
according to Seventh Report of the Joint National 
Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC 7) (Chobanian 
et al., 2003). The classification was as follows; Normal; 
Systolic Blood Pressure (SBP) < 120 mmHg and Diastolic 
Blood Pressure (DBP) < 80 mmHg, prehypertension; 
SBP 120-139 mmHg and DBP 80-89 mmHg, Stage I 
hypertension; SBP 140-159 mmHg and DBP 90 - 99 
mmHg and Stage II hypertension; SBP is >160mm of 
Hg and DBP > 100mm of Hg.
Dyslipidemia
Patients were considered dyslipidemic based on 
elevated cholesterol or serum triglycerides levels. A 
total cholesterol (TC) level > 200 mg/dL or triglyceride 
(TG) level > 150 mg/dL was considered as abnormal21. 
Similarly, low density lipoproteins (LDL) > 100 mg/dL or 
high density lipoproteins (HDL) < 40 mg/dL in men and 
< 50 mg/dL in women were considered for dyslipidaemia.
Data analysis
Data were analyzed using IBM SPSS 22. Cross-
tabulation was performed to assess the percentages of 
different variables with body mass index. Chi-square 
test was used to estimate the association of demogrpahic 
variables and to examine the proportions of disease 
prevalence with respect to obesity class. Multivariate 
logistic regression analysis was performed to assess the 
association of obesity class, odds ratios (with normal 
weight as the reference point), with hypertension and 
dyslipidemia. An alpha value of less than 0.05 was 
considered statistically significant. 
RESULTS
From December 2015 to June 2016, a total of 2708 
eligible diabetics were enrolled, out of which 62% were 
male and 38% were female. 
Patient’s basic demographics
Patient’s basic demographics are summarized in 
Table I. As per obesity class groups, most of the subjects 
belonged to overweight category (37.1%) followed by 
normal weight (27.4%), obesity class I (22.7%), obesity 
class II (7.6%) and obesity class III (2.1%) (Table I). 
Maximum number of patients, 1036 (38.3%), were 
within 46 – 55 years of age with major contribution 
from overweight category (39.4%) followed by normal 
weight population (27.4%). Out of total enrolments, 
62% were males and 38% were females, yet exhibited 
equal frequency distribution in majority of obesity class 
categories (Table I). Likewise, population frequency 
distribution for smoking status and neuropathy were 
almost similar for the obesity classes, when estimated for 
their presence (YES) or absence (NO) (Table I).
Prevalence of neuropathy in enrolled population 
was 26.9% in normal weight class and 36.9% in over 
weight class, while only 23.1% in obesity class I, 7.9% 
in obesity class II and 2.1% in obesity class III developed 
this complication (Table I).
Patient’s clinical characteristics
Next we examined the clinical characteristics of 
our study population – summarized in Table II. As shown 
in Table II, blood pressure profiles, systolic (SBP) and 
diastolic (DBP), demonstrated steady increase with 
increase in obesity. Similarly, triglycerides and cholesterol 
exhibited continual increase in their mean values with 
increase in obesity – a clear manifestation in obesity 
class III subjects having extremely higher mean values 
for triglycerides (206.9±96.6) and cholesterol (244±45.5) 
(Table II). Moreover, HDL mean values were also higher 
in population residing in normal weight and obese class 
I categories, while LDL was found higher in obese class 
III subjects (Table II). 
Frequency distribution of hypertension stages and 
un-controlled lipid profiles among obesity classes 
As shown in  Table  I I I ,  more  than 65% of 
normotensive patients, 29.8% of the total, were either 
in normal body weight category (33.2%) or in over 
weight category (34.3%). On the other hand, based on 
hypertension stages, as for overweight plus obesity 
class I categories, more than 50% of the patients with 
pre-hypertensive stage, stage I and II were representing 
either in over weight (Pre-HTN: 37.9%, Stage-I: 38.3%, 
Stage-II: 38.1%) or in obesity class I category (Pre-HTN: 
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TABLE I - Patient’s basic demographics
Characteristics
Obesity Class (Body Mass Index, kg/m2)
 Under Weight
Normal 
Weight
Over 
Weight
Obesity 
Class 1
Obesity 
Class II
Obesity 
Class III
 (<18.5) (18.5-24.9) (25-29.9) (30-34.9) (35-39.9) (>40)
Total
n=2708
n=82 
3%)
n=743 
(27.4%)
n=1005 
(37.1%)
n=615 
(22.7%)
n=206 
(7.6%)
n=57 
(2.1%)
Age (Years)
<25 50 13 (26%) 26 (52%) 8 (16%) 2 (4%) 0 (0%) 1 (2%)
25-35 178 13 (7.3%) 58 (32.6%) 54 (30.3%) 37 (20.8%) 15 (8.4%) 1 (0.6%)
36-45 668 15 (2.3%) 140 (20.9%) 248 (37.1%) 179 (26.8%) 70 (10.5%) 16 (2.4%)
46-55 1036 22 (2.1%) 285 (27.5%) 408 (39.4%) 218 (21.1%) 76 (7.3%) 27 (2.6%)
56-65 603 14 (2.3%) 174 (28.9%) 210 (34.8%) 155 (5.7%) 39 (6.5%) 11 (1.8%)
>65 173 5 (2.9%) 60 (34.7%) 77 (44.5%) 24 (13.9%) 6 (3.5%) 1 (0.6%)
Gender
Male 1683 51 (3%) 455 (27%) 620 (36.8%) 391 (23.2%) 133 (7.9%) 33 (1.9%)
Female 1025 31 (3.1%) 288 (28.1%) 385 (36.6%) 224 (21.6%) 73 (7.1%) 24 (2.3%)
Current Smoker
Yes 498 17 (3.4%) 123 (24.7%) 176 (35.4%) 115 (23.1%) 59 (11.8%) 8 (1.6%)
No 2210 65 (2.9%) 620 (28.1%) 829 (37.5%) 500 (22.6%) 147 (6.7%) 49 (2.2%)
Neuropathy
Yes 1814 55 (3.1%) 487 (26.9%) 669 (36.9%) 422 (23.3%) 144 (7.9%) 37 (2.1%)
No 894 27 (3.1%) 256 (28.6%) 336 (37.6%) 193 (21.6%) 62 (6.9%) 20 (2.2%)
TABLE II - Blood pressure, HbA1c and lipid profiles as per body weight and obesity class
 Parameters
 
Obesity Class (Body Mass Index, kg/m2) 
Under 
Weight
Normal 
Weight
Over 
Weight
Obesity 
Class I
Obesity 
Class II
Obesity 
Class III
(<18.5) (18.5-24.9) (25-29.9) (30-34.9) (35-39.9) (>40)
SBP (Mean ± SD) 123.4±18.3 131.3±19.7 134.3±19.7 135.4±19.7 136.6±17.8 142.1±28.4
% increase - - 2.3% 3% 4% 8.2%
DBP (Mean ± SD) 81.5±13.4 84.2±1.9 86.2±12.3 86.1±12.8 86.7±11.1 88.8±15
% increase - - 2.4% 2.3% 3% 5.5%
HbA1c (Mean ± SD) 8.1±1.8 8.6±1.9 8.4±1.8 8.7±1.9 8.3±1.6 8.3±1.6
% increase - - -2.3% 1.16% -3.5% -3.5%
HDL (Mean ± SD) 37.9±8.7 42.5±15.8 40.7±12.8 42.1±14.3 41±15.2 41.1±13.6
% increase - - -4.2% -0.9% -3.5% -3.5%
LDL (Mean ± SD) 101.1±19.6 108.1±26.4 109.9±30.9 112.2±33.5 110.7±28.7 113.2±28.1
% increase - - 1.7% 3.79% 2.4% 4.7%
Triglycerides (Mean ± SD) 180.6±72.5 181.6±61.9 183.2±65.9 182.7±65.8 184.6±64.5 206.9±96.6
% increase - - 0.9% 0.6% 1.65% 14%
Cholesterol (Mean ± SD) 210.1±42.9 220.4±46.3 216.6±49.9 217±47.1 224.2±50.4 244±45.5
% increase - - -1.7% -1.5% 1.7% 10.7%
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22.7%, Stage-I: 24.3%, Stage-II: 25.8%) (Table III). Out 
of total subjects (498) having positive smoking status, 
223 (44.8%) had hypertension and 110 (22.1%) were 
found pre-hypertensive (Table III). As for lipid profiles, 
combining together obesity class I, class II and class III 
subjects, almost 40.7% subjects had uncontrolled total 
cholesterol (TC), 39.1% with uncontrolled triglycerides 
(TG), 40.4% with un-controlled low density lipoproteins 
(LDL) and 36.7% with un-controlled high density 
lipoproteins (HDL) (Table III). 
Prevalence of hypertension and dyslipidaemia in 
obese diabetics
Furthermore, when percentage changes were 
estimated with regards to hypertension prevalence 
between normal weight and obesity class III population, 
the prevalence of hypertension increased significantly in 
obesity class III subjects (53.6%), a percentage increase of 
41.8%, in comparison to normal weight population (37.8%) 
(Table IV). When evaluated for gender; male population 
in obesity class III exhibited a percentage increase of 
19.3% in the prevalence of hypertension compared to 
normal weight counterparts, while female population 
demonstrated a negative trend (Table IV). Moreover, 
population ≤ 45 years of age in obese class III category 
demonstrated a significant increase in hypertension 
prevalence, i-e., an increase of 50%, compared to normal 
weight subjects (Table IV). Similar trend was observed 
in smoking population of obese class III category, i-e., a 
percentage increase of 22.7% (Table IV). 
Data further demonstrated that compared to normal 
weight subjects, obese class III subjects had 27.3% 
increase in the prevalence of dyslipidaemia (Table IV). 
Additionally, unlike negative trend observed in female 
subjects in the prevalence of hypertension, female subjects 
in obesity class III category exhibited 27.2% increase 
in dyslipidaemia compared to normal weight subjects 
(Table IV). Conversely, males demonstrated a significant 
decrease in dyslipidaemia (57.8%) prevalence with 
increasing obesity. Besides, we also observed an upward 
trend in the prevalence of dyslipidaemia when examined 
for smoking status (20.94%) and in subjects ≤ 45 years of 
age (14%) (Table IV). 
Association of hypertension and dyslipidaemia 
with obesity in diabetics
Finally, we aimed at estimating an association of 
different obesity classes with that of hypertension and 
dyslipidaemia. Data demonstrated significant association 
of hypertension with obesity classes, nonetheless, with 
higher propensity in obesity class III category (OR; 1.9, 
p=0.02) versus normal body weight subjects (Table V). 
Moreover, the chances of dyslipidaemia were found 
higher.
TABLE III - Hypertension stages and un-controlled lipid profiles according to patient’s body weight and obesity class measurements
Characteristics Obesity Class (Body Mass Index, kg/m2)
 Under 
Weight
Normal 
Weight
Over 
Weight
Obesity 
Class I
Obesity 
Class II
Obesity 
Class III
(<18.5) (18.5-24.9) (25-29.9) (30-34.9) (35-39.9) (>40)
Normal Total n=808 42 (5.2%) 268 (33.2%) 277 (34.3%) 161 (19.2%) 45 (5.7%) 15 (1.9%)
Prehypertension 686 20 (2.9%) 177 (25.8%) 260 (37.9%) 156 (22.7%) 62 (9.1%) 11 (1.6%)
HTN Stage1 786 15 (1.9%) 193 (24.6%) 301 (38.3%) 191 (24.3%) 71 (9.1%) 15 (1.9%)
HTN Stage2 341 4 (1.2%) 77 (22.6%) 130 (38.1%) 88 (25.8%) 27 (7.9%) 15 (4.4%)
Un-controlled Lipid Profiles
TC (> 200 mg/dL) 901 29 (3.2%) 211 (23.4%) 294 (32.6%) 248 (27.5%) 94 (10.4%) 25 (2.8%)
TG (> 150 mg/dL) 996 28 (2.8%) 245 (24.6%) 334 (33.5%) 265 (26.6%) 99 (9.9%) 25 (2.5%)
LDL (> 100 mg/dL) 755 19 (2.6%) 168 (22.9%) 251 34.1 203 (27.6%) 74 (10.1%) 20 (2.7%)
HDL  
(men; > 40 mg/dL), 
women ( > 50 mg/dL)
611 19 (3.1%) 149 (24.4%) 219 (35.8%) 145 (23.7%) 62 (10.1%) 17 (2.8%)
Abbreviations: Normal; SBP < 120 mmHg, DBP 80 mmHg, Prehypertension; SBP 120-139 mmHg, DBP 80-89 mmHg, HTN 
Stage1; SBP 140-159 mmHg, DBP 90 - 99 mmHg, HTN Stage2; SBP >160mm of Hg , DBP > 100mm of Hg, TC; Total Cholesterol, 
TG; triglycerides, LDL; low density lipoproteins, HDL; high density lipoproteins 
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DISCUSSION
Numerous  l i te ra ture  repor ts  sugges t  tha t 
hypertension, dyslipidaemia and diabetes are common 
conditions associated with obesity (Anari et al., 2017; 
Nguyen et al., 2008). In our data we found overt 
representation of diabetics in overweight category, mostly 
males, between 46 – 55 years of age, demonstrating 
continual increase in mean hypertension and cholesterol 
values with increasing obesity. Moreover, obese class 
III population exhibited percentage increases, compared 
to normal weight population, in the prevalence of 
hypertension and dyslipidaemia, yet with variations 
with regards to age and gender. Likewise, hypertension 
TABLE IV - Changes in hypertension & dyslipidaemia prevalence by obesity class
Parameters
Changes in Hypertension Prevalence
Normal (%) Obese Class III (%) % Increase/Decrease
Total 37.8 53.6 41.80
Gender
Male 41.90 50 19.30
Female 58.10 50 -13.90
Age
≤ 45 17.80 26.70 50
>45 82.20 73.30 -10.80
Smoking 16.30 20 22.70
Neuropathy 65.5 64.90 -0.92
Changes in Dyslipidaemia Prevalence
Normal (%) Obese Class III (%) % Increase/Decrease
Total 40 54.9 27.20
Gender
Male 50.50 32 -57.80
Female 49.50 68 27.20
Age
≤ 45 33.30 38.70 14
>45 66.67 61.30 -8.80
Smoking 12.65 16 20.94
Neuropathy 72.70 77.50 6.20
TABLE V - Multivariate logistic regression – Odds of hypertension and dyslipidaemia prevalence with increasing obesity class
Multivariate Logistic Regression
Weight & 
Obesity Class
Hypertension Dyslipidaemia
OR 95% CI p-value OR 95% CI p-value
Normal 1(Reference) 1(Reference)
Under Weight 0.51 0.30 - 0.86 0.012* 0.8 0.36 - 1.75 0.56
Overweight 1.32 1.09 - 1.61 0.005** 0.75 0.52 - 1.07 0.11
Obese Class I 1.45 1.16 - 1.81 0.001** 0.89 0.61 - 1.32 0.57
Obese Class II 1.51 1.10 - 2.01 0.01* 1.11 0.64 - 1.92 0.71
Obese Class III 1.91 1.10 - 3.29 0.02* 1.94 0.57 - 6.59 0.29
* p 0.05 - < 0.01, ** p < 0.01 – 0.0005
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exhibited strong association with obesity as demonstrated 
by significant increase in hypertension with increasing 
obesity – maximum in obesity class III. Similar trends 
were observed for dyslipidaemia, i-e., higher likelihood of 
dyslipidaemia with increasing obesity, yet the association 
was not statistically significant. 
According to literature reports, obesity can contribute 
towards hypertension, dyslipidaemia and hyperglycaemia, 
thus can modulate cardiovascular disease (CVD) risks 
(LeRoith, 2008). In this regard, HbA1c, triglycerides, 
total cholesterol and blood pressure, SBP & DBP, has been 
shown to associate significantly with obesity in diabetics 
of Indian origin (Prabodh et al., 2012). Interestingly, 
similar to the above mentioned observations, in our 
population of Indian sub-continent, i-e., in Pakistan, we 
observed linear increase in most of the biological factors, 
such as SBP, DBP, triglycerides and total cholesterol 
with increase in obesity class – demonstrating maximum 
mean values in patients representing obesity class III. 
Several literature evidences suggest that most of diabetics, 
irrespective of gender, having hypertension, dyslipidaemia 
and obesity were frequently reported in patients above 50 
years of age (Anari et al., 2016). Our data corroborated the 
above mentioned findings, however, when ascertained for 
percentage changes, from normal body weight to obesity 
class III, in the prevalence of hypertension, diabetes and 
dyslipidaemia, subjects between 30 – 45 years of age 
exhibited maximum percentage increases, i-e., higher 
prevalence of these diseases with increasing obesity. 
We also, observed that most of our enrolled patients had 
neuropathy, this higher frequency might be attributed to 
higher HbA1c values rather than obesity per se, since we 
did not observe an increasing trend with increase in obesity 
class in patients with neuropathy. Seemingly, obesity alone 
is not linked to neuropathy rather a risk factor in obese 
diabetics, which can aggravate neuropathic pain due to 
obesity associated inflammation (Hozumi et al., 2016).
Numerous literature evidences suggest that 
hypertension and diabetes are strongly associated with 
body weight and obesity (Nguyen et al., 2008; Patel et al., 
2016). A study conducted in Spain showed that diabetics 
having obesity are more prone to develop hypertension 
and dyslipidaemia - 92.6% patients had dyslipidaemia and 
73.7% had hypertension (Gomis et al., 2014). Likewise, it 
is reported that the prevalence of hypertension in western 
population increase with age and obesity, yet even adjusted 
for age and obesity, hypertension prevalence was still 
1.5 times higher in diabetics (Turner et al., 1993). In this 
context, our data further substantiated this concept that 
hypertension is strongly associated with increasing body 
weight class in diabetics of Lahore Pakistan, exhibiting 
higher susceptibility of hypertension with increasing 
obesity. Studies also demonstrated that type II diabetes 
and hypertension are strongly associated with end 
organ damage, the retina and kidney, while the similar 
association is less evident for obesity and dyslipidaemia 
(Fong et al., 2004; Wong, Mitchell, 2004). These data and 
literature evidences suggested that hypertension along 
with diabetes are key players in augmenting diabetic 
complications and cardiovascular disease risks rather than 
obesity and dyslipidaemia, nonetheless, it is highly likely 
that co-existence of obesity and dyslipidemia might further 
aggravate the clinical condition. 
Moreover, the association between diabetes and 
metabolic dysregulators, such as dyslipidemia and obesity 
have been reported previously (Sheth et al., 2015). In this 
regard, a strong association has been observed between 
HbA1c of diabetics (type II) and dyslipidemic obesity, with 
strong positive association of HbA1c with triglycerides 
and cholesterol (Prabodh et al., 2012; Sheth et al., 2015). 
Our data suggested that dyslipidemia prevalence was 
significantly increased in diabetics in obesity class III, 
predominantly in females and those having positive 
smoking status. These findings were further supported 
by association estimates suggesting that dyslipidemia 
was significantly higher in obesity class III diabetics 
in comparison to normal and over-weight subjects. 
Interestingly, when dyslipidemia prevalence was estimated 
with regards to gender, compared to males, females were 
demonstrating higher percentage increases in dyslipidemia 
prevalence from normal weight to obesity class III 
category. Similar findings have been reported before, 
suggesting higher obesity and dyslipidemia predisposition 
in female diabetics – 4.6 times higher general obesity and 
8 times higher central obesity than males (Anari et al., 
2016). However, despite positive association between 
obesity and diabetes along with contributory effects of 
hypertension and dyslipidemia in aggravating diabetic 
complications and treatment intricacies, not a single study 
has been reported from Pakistan describing association 
of hypertension and dyslipidemia in obese diabetics and 
plausible treatment options.
Limitations
Our study has number of limitations due to 
observational design of the study, therefore, many 
demographic variables, such as education, occupation 
and financial status cannot be examined in predicting their 
roles in hypertension and dyslipidemia prevalence in obese 
diabetics over a period of time. Similarly, data cannot 
be extracted to know that which pathological condition 
Z. Saleem, H. Saeed, Z. A. Khan, M. I. H. Khan, F. K. Hashmi, M. Islam, A. Bashir, S. Sadeeqa
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developed first and the impact of exposure duration of a 
particular risk/concomitant disease, e.g., hypertension, 
leads to another. Moreover, patient’s associated factors 
such as sedentary life style, dietary habits were not 
estimated in defining the association of these pathological 
conditions in obese diabetics. Similarly, we are unable to 
estimate the associations based on general and abdominal 
adiposity, since visceral adiposity is now considered a 
major contributor in the development of hypertension, 
insulin resistance, diabetes and dyslipidemia rather than 
BMI (Colditz et al., 1995).
CONCLUSION
In conclusion, hypertension is strongly associated 
with obesity in diabetics, having higher likelihood of 
hypertension that increases with increasing weight and 
obesity class. However, the chances of dyslipidemia 
became vivid in obese diabetics, predominantly in obesity 
class III. However, an association of hypertension and 
dyslipidemia in obese diabetics might warrant a specific 
treatment or self-care and management practices, 
because of heterogeneity of multifaceted risks, severity 
and duration of risk exposure, further complicating the 
unclear etiology of diabetes co-existed with hypertension, 
dyslipidemia and obesity. Therefore, further studies 
are required to determine the unsettled risks, genetic 
and environmental (stress), and duration of exposure 
of these risks in bolstering overt clinical manifestations 
of associated conditions, hypertension, obesity and 
dyslipidemia in diabetics. Moreover, it would be pertinent 
to assess that which co-existed condition develops first in 
diabetics that might initiate or encourage the development 
of another associated condition and which therapeutic and 
non-pharmacological management approach at this critical 
juncture would be the most suitable option to prevent the 
co-existence of another associated condition. 
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